Table 2. The number of pulmonary adverse drug events (ADEs) when relative reporting ratio (RR) larger than two or the fifth quantile of empirical Bayes geometric mean (EBGM), EB05, larger than two after graphical least absolute shrinkage and selection operator (GLASSO) filtering process implemented in Table 1.
| Drug | # Pulmonary ADEs | Order by EBGM | # Pulmonary ADEs | Order by RR |
|---|---|---|---|---|
| Macitentan | 16 | 1 | 10 | 2 |
| Bosentan | 14 | 2 | 5 | 11 |
| Epoprostenol | 11 | 4 | 9 | 4 |
| Selexipag | 10 | 5 | 10 | 2 |
| Sildenafil | 10 | 6 | 7 | 6 |
| Tadalafil | 10 | 7 | 3 | 44 |
| Beraprost | 7 | 10 | 13 | 1 |
| Nifedipine | 5 | 13 | 5 | 11 |
| Candesartan | 4 | 16 | 3 | 34 |
| Althiazide/Spironolactone | 3 | 20 | 4 | 18 |
| Bisoprolol | 3 | 21 | #N/A | #N/A |
| Imidapril | 3 | 24 | 5 | 11 |
| Azelnidipine | 2 | 30 | 4 | 23 |
| Azilsartan Kamedoxomil | 2 | 31 | 3 | 32 |
| Bendroflumethiazide | 2 | 32 | 3 | 33 |
| Benidipine | 2 | 33 | 5 | 11 |
| Cilnidipine | 2 | 34 | 5 | 11 |
| Doxazosin | 2 | 36 | 3 | 36 |
| Lercanidipine | 2 | 39 | 1 | 90 |
| Nicardipine | 2 | 40 | 5 | 11 |
| Rilmenidine | 2 | 42 | #N/A | #N/A |
| Telmisartan | 2 | 43 | 4 | 30 |